Biokine

Biokine Therapeutics Ltd. is a private, clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2000 by Professor Amnon Peled, a chemokine researcher who serves as the company's CEO and Chief Scientific Officer. The company is focused on the discovery and development of novel therapeutics that target molecular and cellular mechanisms regulating tumor development, metastasis, and immune response. Its scientific foundation rests on the biology of the CXCR4 chemokine receptor, a pathway implicated in cancer cell migration, survival, and resistance to therapy. Biokine's lead product is BKT140, also known as BL-8040, a high-affinity, long-acting CXCR4 receptor inhibitor. According to the company, BL-8040 has completed a successful Phase III trial for stem cell mobilization and Phase I/II studies for immunotherapy in cancer in combination with immune checkpoint inhibitors pembrolizumab (Keytruda, Merck) and atezolizumab (Tecentriq, Genentech/Roche). The compound was licensed to BiolineRx Ltd. (NASDAQ: BLRX) and is being developed clinically in partnership with that company across multiple indications, including stem cell mobilization, acute myeloid leukemia (AML), and pancreatic carcinoma in combination with chemotherapy and anti-PD-1 therapy. Beyond its lead asset, Biokine has developed a suite of proprietary discovery technologies. MigHit™ is a phenotypic screening platform designed to identify small molecules that target migration and survival pathways in cancer. ImmunHit™ is a platform technology for identifying small molecules that modulate interferon-gamma (IFN-γ)-mediated immune responses in cancer and inflammation. These platforms support the company's internal preclinical pipeline of novel drug candidates. The company describes itself as a private, well-integrated, venture-capital-funded, and revenue-generating entity. Its management team is composed of biopharma veterans with experience advancing drugs from concept to advanced clinical studies. Biokine's research has been published in peer-reviewed journals including Blood, JCI, and Science, reflecting its scientific orientation. The company's mission is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis and to developing novel therapeutics against these diseases.

Biokine Therapeutics Ltd. was founded in 2000 in Israel by Professor Amnon Peled, a researcher specializing in chemokine biology, particularly the CXCR4 receptor. The company was established as a private biopharmaceutical venture with a focus on translating basic research on tumor development and metastasis into novel therapeutics. Professor Peled, who serves as CEO and Chief Scientific Officer, has a Ph.D. from the Weizmann Institute of Science and has held a position at the Gene Therapy Institute at Hadassah Medical Center in Jerusalem, where he directs a laboratory studying chemokines and chemokine receptors in cancer and immune diseases. His prior industry experience includes Millennium Pharmaceuticals, where he led a group studying CXCR4 function in allergy. From its early years, Biokine concentrated on the CXCR4 pathway, which plays a central role in cancer cell migration, survival, and resistance to therapy. The company's lead compound, BKT140 (also known as BL-8040), was developed as a high-affinity, long-acting CXCR4 receptor inhibitor. According to the company, BL-8040 has completed a successful Phase III trial for stem cell mobilization and Phase I/II trials for immunotherapy in cancer in combination with immune checkpoint inhibitors pembrolizumab (Keytruda, Merck) and atezolizumab (Tecentriq, Genentech/Roche). The compound was licensed to BiolineRx Ltd. (NASDAQ: BLRX) and is being developed clinically in partnership with that company for multiple indications, including stem cell mobilization, acute myeloid leukemia (AML), and pancreatic carcinoma in combination with chemotherapy and anti-PD-1 therapy. In addition to its lead asset, Biokine has built proprietary discovery platforms. MigHit™ is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer. ImmunHit™ is a platform technology that enables identification of small molecules targeting IFN-γ-mediated immune response in cancer and inflammation. These platforms have supported advanced preclinical research on novel drug candidates discovered in-house. The company describes itself as a private, well-integrated, venture-capital-funded, and revenue-generating entity. Its management team includes biopharma veterans with a track record of taking drugs from idea to advanced clinical studies. Biokine's scientific work has been published in peer-reviewed journals such as Blood, JCI, and Science. The company is located in Rehovot, Israel, a hub of life sciences activity. As of the latest available information, Biokine remains a private company focused on advancing its clinical and preclinical pipeline.

• 2000

  Biokine Therapeutics founded in Israel by Professor Amnon Peled.

• Lead compound BKT140 (BL-8040) licensed to BiolineRx Ltd. (NASDAQ: BLRX) for clinical development.

• BL-8040 completed successful Phase III trial for stem cell mobilization.

• BL-8040 completed Phase I/II trials for immunotherapy in cancer in combination with pembrolizumab and atezolizumab.

Clinical-stage biopharmaceutical company focused on CXCR4-targeted cancer therapeutics and immune-response pathway modulators.

• BKT140 / BL-8040

  A high-affinity, long-acting CXCR4 receptor inhibitor. Indications include stem cell mobilization (Phase III), AML (Phase 2b), and pancreatic carcinoma in combination with chemotherapy and anti-PD-1/KEYTRUDA (Phase 2a). Licensed to BiolineRx Ltd. (NASDAQ: BLRX).

• MigHit™

  A phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer.

• ImmunHit™

  A platform technology enabling identification of small molecules targeting IFN-γ-mediated immune response in cancer and inflammation.

1. 1Biokine Therapeutics – A New Horizon For Cancer Therapybiokine.com
2. 2About Biokine – Biokine Therapeuticsbiokine.com
3. 3Management Team – Biokine Therapeuticsbiokine.com
4. 4Biokine (Israel) – Wikidatawikidata.org